What Мальтофер Treats: Main Uses and Benefits

This preparation is commonly used for the treatment and prevention of iron deficiency. It is relevant for managing both established Iron Deficiency Anemia (IDA) and latent iron deficiency (low iron stores).

The preparation supports the patient during episodes of heightened discomfort and contributes to improved day-to-day comfort by helping address the physical and cognitive strain associated with the deficit. This iron complex is applied across domains where additional symptomatic support is needed. Mini-Quote: “This application supports the patient during difficult episodes of discomfort.”

It is considered relevant for managing symptom clusters that include pronounced fatigue, reduced physical capacity, and cognitive issues such as dizziness or poor concentration. It is also applied in clinical settings for patient groups with high physiological stress, notably pregnant and lactating women, and is relevant when the patient experiences discomfort or sensitivity to other forms of iron supplementation.

Quick Fact: Used for managing Fatigue and Low Energy

Regulatory References

1. New Zealand Medsafe Consumer Medicine Information

Official Eligibility and Contraindications

The use of Мальтофер (Iron Polymaltose Complex) is defined by its ability to treat confirmed iron deficiency and by a clear set of contraindications based on iron status and known allergies.

---

Classification	Who Must Not Use the Medicine (Contraindications)
Iron Status	Individuals with anaemia not caused by iron deficiency (e.g., haemolytic anaemia, B12 deficiency).
	Individuals with iron overload (e.g., haemochromatosis, haemosiderosis) or disturbances in iron utilisation (e.g., thalassaemia).
Hypersensitivity	Patients with a known hypersensitivity (allergy) to the active substance, Iron Polymaltose Complex, or any of the excipients.
Concomitant Use	Must not be administered at the same time as injectable iron preparations.

---

Age and Population Eligibility:

• Adults and Adolescents (12 years): Eligible for treatment and prevention of iron deficiency.
• Children (< 12 years): Oral drops or syrup formulations are generally considered more suitable for this age group, though tablet forms may be contraindicated or not recommended due to limited efficacy data for the specific dose.
• Pregnancy and Lactation: Use is documented and generally considered safe when taken as directed; however, consultation with a healthcare professional is advised to assess the benefit/risk ratio.

Certain oral formulations containing sugars or sorbitol are restricted for patients with rare hereditary problems such as fructose intolerance or sucrase-isomaltase insufficiency.

Interactions with other medicines and products — official regulatory information for Мальтофер

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Parenteral iron preparations (Injectable iron medicines).
Specific interacting medicines (if explicitly listed):	Tetracycline (Documented as not interacting). Aluminium hydroxide (Antacids) (Documented as not interacting).
Mechanistic basis of interactions (only if stated in label):	Pharmacokinetic interaction: Reduced absorption (Specific to co-administration with parenteral iron). Lack of typical ionic interaction (Specific to antacids and tetracycline).
Timing-based interaction rules (if applicable):	No mandatory timing separation rule is required for co-administration with tetracycline or aluminium hydroxide.
Interaction-related restrictions:	Co-administration with parenteral iron is not recommended.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation
Interaction severity classification:	Not recommended (Specific to combination with parenteral iron). No significant interaction (Specific to combination with tetracycline and aluminium hydroxide).
Regulatory basis:	Information is based on official Data Sheet and Summary of Product Characteristics (SmPC) findings.

---

Resulting Interaction Structure

Official Interaction Statements:

• The co-administration of this oral preparation with parenteral iron medicines is not recommended.
• Co-administration with injectable iron results in a reduced absorption of the oral iron component.
• The absorption of the iron complex was not reduced when co-administered with aluminium hydroxide (antacids).
• Studies documented no significant reduction in the absorption of tetracycline; therefore, no mandatory timing separation is required when co-administering with tetracycline.

Connection to the overall interaction profile

The overall interaction profile is primarily characterized by a documented restriction on co-administration with parenteral iron, which is stated to reduce the oral iron's absorption. Regulatory documents explicitly detail that this preparation’s unique structural stability avoids the typical ionic chelation interactions seen with simple iron salts. This specific finding eliminates the need for timing separation rules usually applied to other oral iron formulations when taken with substances like antacids or tetracycline.

Controlled Iron Release and Regulated Intestinal Uptake

The mechanism begins with the unique structure of Iron(III)-hydroxide polymaltose complex, which enables the controlled release of non-ionic Fe^3+ in the gastrointestinal tract. Unlike simple iron salts, this complex prevents the passive diffusion of reactive iron ions. The iron is absorbed via an active, regulated process, primarily endocytosis by the intestinal enterocytes, an interaction that is highly proportional to the body's physiological need for iron. This mechanism facilitates the efficient assimilation of iron while supporting gastrointestinal tolerance.

---

Systemic Transport and Heme Synthesis

Once absorbed, the iron immediately binds to the transport protein Transferrin for systemic delivery. The process remains subject to the body's iron regulatory feedback loop, which is governed by the hormone Hepcidin, modulating the potential for high absorption in iron-replete states. The iron is directed to the bone marrow, where it serves as the essential substrate for the Heme Synthesis Pathway. Providing this key component accelerates erythropoiesis, which is the fundamental physiological process that ultimately results in the production of functional hemoglobin for oxygen transport.

How to Use Мальтофер

Мальтофер (Iron(III)-hydroxide polymaltose complex) is administered exclusively via the oral route, with standard procedural conditions to ensure proper use. Its usage is determined by the severity of the iron deficit, defining the required daily dose and the total duration of the course.

---

Official Administration Guidelines

Feature	Detail
Route of Administration	Oral use only.
Standard Daily Dosing	Treatment for adults (ge 12 years) typically ranges from 100 mg to 200 mg elemental iron daily; 100 mg elemental iron daily for prevention.
Timing in Relation to Meals	Must be taken during or immediately after a meal (with food).
Duration Principle	Treatment must continue for an extended period, often several months following the normalization of hemoglobin, to ensure the full replenishment of body iron stores.

---

Form and Population Usage Principles

Administration frequency is set as once daily, though the total amount may be divided into separate doses. A key instruction is the timing with meals, a requirement for the administration of the iron complex.

Regarding dosage forms, film-coated tablets must be swallowed whole and are not to be chewed. For doses below 100 mg elemental iron, particularly in the pediatric population (lt 12 years), liquid forms such as oral drops or syrup are required for accurate measurement. These liquid preparations can be mixed with fruit or vegetable juices prior to intake.

Research evidence / Overview of studies for Мальтофер

Evidence for Use in Iron Deficiency Anemia (IDA)

Research has studied this specific oral iron preparation, Iron(III)-hydroxide polymaltose complex, in numerous clinical evaluations, including Randomized Controlled Trials (RCTs) and systematic reviews, spanning over two decades of documented research. The research was studied in individuals with iron deficiency or established Iron Deficiency Anemia ( IDA). These trials were generally conducted over short- to intermediate-term observation periods.

In these studies, researchers examined patient groups typically monitored for two to three months. The trials monitored changes in key iron markers, such as Hemoglobin ( Hb), Serum Ferritin ( SF), and Transferrin Saturation ( TSAT). Comparative studies reported measurements where outcomes were observed in comparator trials. Research highlighted changes measured in patient-reported outcomes describing perceived discomfort related to the gastrointestinal system, with some studies describing patterns where reported discomfort differed between treatments.

Evidence in Specific Populations: Pregnancy and Children

Research has specifically explored the effect of this preparation in special groups, including pregnant women and children across various age ranges. In pregnant women with IDA, studies examined the preparation's influence on Hb and SF levels. Findings indicated that outcomes were measured against other standard iron preparations, and reports described patterns related to patient-reported outcomes describing perceived discomfort.

However, the data available for children and infants appear to be less consistent. Research describes findings in pediatric populations that were often mixed or highly variable. This is partly because evidence quality varies across studies in this group. Few data are available from large-scale, long-term studies in this particular population.

What is Still Uncertain About the Research for Мальтофер

The current evidence highlights what is known—and what is still uncertain. Research is ongoing, but data for certain groups remain insufficient. Specifically, the comparative evidence is lacking for certain specialized populations, and there is limited information for long-term outcomes regarding the sustained maintenance of iron stores after treatment completion. These research questions studies explore and research describes as the main evidence gaps in the current body of work.

Key Studies & References Meta-analysis of iron polymaltose complex in the treatment of iron deficiency and iron deficiency anemia.

Common questions about Мальтофер (FAQ)

---

Q: Does Мальтофер cause constipation more or less than other iron supplements?

A: Regulatory documents indicate that the preparation is associated with a lower risk of constipation compared to traditional iron salts. Despite this, constipation is still officially listed as a common side effect in the product's safety information.

---

Q: How long does it typically take to feel an effect from taking Мальтофер?

A: Official information indicates that it may take a few weeks before symptoms of iron deficiency begin to lessen. However, treatment for an established iron deficit must continue for several months to fully correct and replenish the body's iron stores, as directed by official guidance.

---

Q: Is it normal for my stool to change color while taking Мальтофер?

A: Yes, a change in stool color, such as black stool, is officially classified in regulatory documents as a Very Common effect. This discoloration is generally considered to be of no clinical significance.

---

Q: Is it true that Мальтофер causes less stomach upset than older iron supplements?

A: Official information often describes this preparation as having a reduced incidence of gastrointestinal side effects compared to traditional ferrous iron salts. Studies suggest that the unique structure of the iron complex contributes to this pattern of reduced digestive discomfort.

---

Q: How quickly does Мальтофер start raising iron levels in the blood?

A: Measurable changes in key iron markers, such as Hemoglobin, have been observed in studies after approximately four weeks of treatment. Achieving full iron store correction, however, requires adherence to the entire prescribed course, which typically lasts several months.

---

Q: Can Мальтофер be taken with coffee or tea?

A: Studies have demonstrated that the absorption of the iron complex is not reduced when co-administered with known inhibitors like coffee or tea. Official instructions recommend taking the medicine during or immediately after a meal.

---

Q: Why does Мальтофер come in different forms for children versus adults?

A: The different forms, such as oral drops and syrup, are provided to allow for the accurate measurement of smaller, age-appropriate doses that the 100 mg tablets cannot provide for the pediatric population.

---

Q: What should I do if I experience nausea after taking Мальтофер?

A: Nausea is officially listed as a common side effect of this preparation. Official instructions recommend taking the medicine during or immediately after a meal, which may support tolerance.

---

Q: How long is a typical course of treatment with Мальтофер?

A: For the specific correction of an iron deficiency, the treatment typically lasts for three to six months. Treatment for store replenishment may continue for several months following the normalization of blood Hemoglobin levels.

---

Q: Can Мальтофер be taken at the same time as calcium supplements?

A: Its unique structural stability means that absorption is not significantly affected by substances like antacids, eliminating the need for strict timing separation often required with other iron types. No special timing separation is required for the complex.

---

Q: Is Мальтофер iron a type of chelated iron?

A: The active ingredient, Iron(III)-hydroxide polymaltose complex, is officially described in regulatory texts as an iron-polysaccharide complex. This structure makes it distinct from simple ionic iron salts.

---

Q: Can children or infants take Мальтофер?

A: Official documentation confirms that the liquid forms (drops and syrup) are available for the treatment of iron deficiency in children and infants. Usage must be based on the specific dosage prescribed for the child's age.

---

Q: Can Мальтофер be crushed or mixed into drinks?

A: Regulatory guidance specifies that the film-coated tablets must be swallowed whole and should not be crushed or chewed. However, the liquid formulations, such as drops and syrup, are designed to be mixed with fruit or vegetable juices.

---

Q: Why do some people take Мальтофер to boost energy levels?

A: Official information indicates that symptoms of iron deficiency often include feelings of chronic fatigue and tiredness. Therefore, the purpose of correcting the underlying iron deficit is to address common symptoms like fatigue and tiredness.

---

Q: Is Мальтофер suitable for vegetarians or vegans?

A: Official sources note the active ingredient is a synthetic complex and is generally free from ingredients of animal origin. Based on this, the product is often considered suitable for vegetarians and vegans.

---

Q: What color are the Мальтофер tablets or liquid?

A: Official product information describes the film-coated tablets as being brown-maroon in color. The liquid preparations (syrup and oral drops) are typically described as a brown solution.

---

Q: Does Мальтофер need to be stored in the refrigerator?

A: Regulatory instructions specify that the medicine must be stored at a temperature not exceeding 25°C and must not be frozen. It does not contain a requirement for mandatory refrigeration.

---

Q: Are there different strengths of Мальтофер available?

A: Yes, the medicine is available in multiple forms that provide different dosing options. These include 100 mg elemental iron tablets, as well as syrup and oral drops, which allow for a range of smaller measured doses.

---

Q: Is Мальтофер iron derived from animal or plant sources?

A: The active ingredient in this medicine is a synthetic complex. Official sources confirm that it is generally free from ingredients that are derived from either animal or plant sources.

---

Q: Is Мальтофер considered a highly absorbable form of iron?

A: The product is described as having a unique mechanism where absorption occurs via active uptake in the gut. This system is described as controlled and regulated by the body, which differs from the passive absorption of simple iron salts.

---

Q: What are the primary reasons people discontinue using Мальтофер?

A: The official adverse effects often cited as reasons for discontinuation are gastrointestinal disorders, such as nausea and constipation. These are the most common side effects reported in regulatory documents.

How to Store and Dispose of Maltofer

Official regulatory labeling dictates specific conditions for storing and disposing of Maltofer (iron polymaltose) to maintain its quality.

Storage Requirements

Condition	Regulatory Rule
Temperature	Store at a temperature not exceeding 25 C; Do not freeze.
Environment	Keep the product in the original package and store in a dry place.
Stability	Oral solutions (syrup/drops) are stable for 3 months after the bottle is opened.
Child Safety	Keep out of the sight and reach of children.

Disposal Requirements

Disposal instructions require that unused or expired Maltofer must be disposed of in accordance with local requirements. The product must not be disposed of via wastewater or household waste.